Efficacy of Electrochemotherapy with Bleomycin, Oxaliplatin, or Oxaliplatin with Bevacizumab in the Treatment of Colorectal Hepatic Metastases in Rats
Cancers · 23.08.2025 · 17 (17) · 2753
DOI: 10.3390/cancers17172753 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 23.08.2025. Verfasst von Antonios E Spiliotis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Campus Charité Mitte, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Homburg Research Funding Program.
Abstract (Originalsprache)
Background/Objectives: Electrochemotherapy (ECT) has been shown to be effective in treating colorectal liver metastases when combined with bleomycin (BLM). Based on this promising finding, we compared in this study the efficacy of BLM with oxaliplatin (OXP) and bevacizumab (BVZ) in ECT.
Methods
WAG/Rij rats were randomized into three groups and underwent ECT with intravenous injection of BLM, OXP, or OXP with BVZ for eight days following hepatic tumor cell implantation. Ultrasound and photoacoustic imaging served to assess oxygen saturation (SO2) and hemoglobin concentration (HbT) of the developing tumors. Tissue samples were analyzed by histology and immunohistochemistry.
Results
BLM treatment significantly reduced SO2 (33.7%) and HbT (12.7%) levels compared to pretreatment values. In contrast, the OXP-treated groups exhibited only modest reductions in both parameters. BLM also induced a markedly higher necrosis rate (82.6%) compared to OXP and OXP/BVZ (11.0% and 26.3%). Conversely, OXP-treated tumors exhibited higher apoptosis rates. Furthermore, BLM treatment led to a decrease in tumor cell proliferation and a reduction in inflammatory response compared to the other treatments. Notably, BLM caused a 26.2% reduction in CD31-positive microvessels, which was significantly higher than that observed in the OXP group.
Conclusions
BLM showed a more effective anti-tumor activity than OXP, suggesting its preferred use as chemotherapeutic agent in ECT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Campus Charité Mitte, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.
- Institute for Clinical and Experimental Surgery, Saarland University, PharmaScienceHub (PSH), 66421 Homburg, Germany.
- Department of Cardiovascular Surgery, Heart Center Niederrhein, Helios Hospital Krefeld, 47805 Krefeld, Germany.
- Department of General Surgery, Vascular-, Visceral- and Pediatric Surgery, Saarland University Medical Center, 66421 Homburg, Germany.
- Institute for Medical Biometry, Epidemiology and Medical Informatics, Saarland University Medical Center, 66421 Homburg, Germany.
ORCID-Profile: Antonios E Spiliotis, Sebastian Holländer, Gudrun Wagenpfeil, Matthias W Laschke, Gereon Gäbelein
Förderung
- Homburg Research Funding Program
Zitieren
APA
Spiliotis, A. E., Kyriakides, O. M., Holländer, S., Wagenpfeil, G., Laschke, M. W., Glanemann, M., & Gäbelein, G. (2025). Efficacy of Electrochemotherapy with Bleomycin, Oxaliplatin, or Oxaliplatin with Bevacizumab in the Treatment of Colorectal Hepatic Metastases in Rats. Cancers, 17(17), 2753. https://doi.org/10.3390/cancers17172753
Vancouver
Spiliotis AE, Kyriakides OM, Holländer S, Wagenpfeil G, Laschke MW, Glanemann M, et al. Efficacy of Electrochemotherapy with Bleomycin, Oxaliplatin, or Oxaliplatin with Bevacizumab in the Treatment of Colorectal Hepatic Metastases in Rats. Cancers. 2025;17(17):2753. doi:10.3390/cancers17172753
BibTeX
@article{Spiliotis2025,
author = {Spiliotis, Antonios E and Kyriakides, Orestis Mallis and Holländer, Sebastian and Wagenpfeil, Gudrun and Laschke, Matthias W and Glanemann, Matthias and Gäbelein, Gereon},
title = {Efficacy of Electrochemotherapy with Bleomycin, Oxaliplatin, or Oxaliplatin with Bevacizumab in the Treatment of Colorectal Hepatic Metastases in Rats},
journal = {Cancers},
year = {2025},
volume = {17},
number = {17},
pages = {2753},
doi = {10.3390/cancers17172753}
}
EUVIMED